Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to treat conditions mediated by PBR, CB2, and NK2 receptors
View Patent ↗The invention relates to the discovery that cis-epoxyeicosatraenoic acids (EETs) bind to and act as agonists of peripheral benzodiazepine receptor and the cannabinoid CB 2 receptor. The invention provides methods of reducing symptoms of conditions whose activity is mediated by these receptors, including inhibiting anxiety, inhibiting the growth of cancer cells expressing peripheral benzodiazepine receptors, and reducing oxygen radical damage to cells, by contacting the cells with a cis-epoxyeicosantrienoic acid, an inhibitor of soluble epoxide hydrolase (sEH), or both. The invention further provides methods of inhibiting irritable bowel syndrome by administering to individuals with inhibiting irritable bowel syndrome a cis-epoxyeicosantrienoic acid, an inhibitor of soluble epoxide hydrolase (sEH), or both. In some embodiments, the method comprises administering to the individual a nucleic acid which inhibits expression of sEH.
1. A method of relieving a condition selected from the group consisting of status epilepticus, other forms of epilepsy, symptoms of opiate withdrawal, insomnia, or mania in a subject in need thereof, said method comprising administering to said subject an effective amount of an agent or agents selected from the group consisting of a cis-epoxyeicosantrienoic acid (“EET”), an inhibitor of soluble epoxide hydrolase (“sEH”), and a combination of an EET and an inhibitor of sEH, wherein the inhibitor of sEH comprises a central pharmacophore comprising a urea, carbamate, or amide; and a carbamate, ester, carbonate or amide approximately 7.5 angstroms from the carbonyl of the central pharmacophore, thereby relieving said condition in said subject.
2. A method of claim 1 , wherein the agent is an EET.
3. A method of claim 1 , wherein the EET is selected from the group consisting of 14,15-EET, 8,9-EET, 11,12-EET or 5,6-EET.
4. A method of claim 1 , wherein the agent is an inhibitor of sEH.
5. A method of claim 4 , wherein the inhibitor of sEH inhibits sEH with an IC 50 of less than about 500 μM.
6. A method of claim 4 , wherein the inhibitor of sEH inhibits sEH with an IC 50 of less than about 0.1 μM.
7. A method of claim 1 , wherein the condition is status epilepticus or other forms of epilepsy.
8. A method of claim 1 , wherein the inhibitor of sEH comprises a polyglycol secondary pharmacophore.
9. A method of claim 1 , wherein the agent is administered orally.
10. A method of claim 1 , wherein the agent is administered by inhalation.
11. A method of claim 1 , wherein the agent is administered by intranasal or pulmonary delivery.
12. A method of relieving a condition selected from the group consisting of status epilepticus, other forms of epilepsy, symptoms of opiate withdrawal, insomnia, or mania in a subject in need thereof, said method comprising administering to said subject an effective amount of an agent or agents selected from the group consisting of a cis-epoxyeicosantrienoic acid (“EET”), an inhibitor of soluble epoxide hydrolase (“sEH”), and a combination of an EET and an inhibitor of sEH, wherein the inhibitor of sEH comprises a central pharmacophore comprising a urea, carbamate, or amide; a carbamate, ester, carbonate or amide approximately 7.5 angstroms from the carbonyl of the central pharmacophore; and inhibits sEH with an IC 50 of less than about 500 μM, thereby relieving said condition in said subject.
13. A method of claim 12 , wherein the agent is an EET.
14. A method of claim 12 , wherein the EET is selected from the group consisting of 14,15-EET, 8,9-EET, 11,12-EET or 5,6-EET.
15. A method of claim 12 , wherein the agent is an inhibitor of sEH.
16. A method of claim 12 , wherein the condition is status epilepticus or other forms of epilepsy.
17. A method of claim 12 , wherein the inhibitor of sEH comprises a polyglycol secondary pharmacophore.
18. A method of claim 12 , wherein the inhibitor of sEH inhibits sEH with an IC 50 of less than about 0.1 μM.
19. A method of claim 12 , wherein the agent is administered by a route of administration selected from the group consisting of oral, inhalation, intranasal and pulmonary delivery.